.Attribute Medication, Published online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec got FDA permission after an unfavorable trial, which highlights the numerous complexities as well as challenges of medicine growth within this environment.